Genocea to Present at September Healthcare Conferences
30 Agosto 2019 - 7:00AM
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical
company developing personalized cancer immunotherapies, today
announced that Chip Clark, president and chief executive officer,
will present at two leading healthcare conferences in September:
- Robert W. Baird’s 2019 Global Healthcare
ConferenceGenocea will participate in a conference
fireside chat to provide background on the company and an update on
its scientific progress, followed by a Q&A session, on
Thursday, September 5 at 2 p.m. Eastern Time at the
InterContinental New York Barclay.
- H.C. Wainwright Annual Healthcare Conference
2019Genocea will present a corporate overview on Tuesday,
September 10 from 3:25 - 3:50 p.m. Eastern Time at the Lotte New
York Palace hotel (Holmes II, 4th Floor).
Live webcasts of both presentations can be accessed by visiting
the "Events and Presentations" tab of the investor relations
section of the Genocea website at http://ir.genocea.com. Replays of
the webcasts will be archived for 90 days following the
conferences.
About Genocea Biosciences, Inc.Genocea is a
biopharmaceutical company developing personalized cancer
immunotherapies. Our unique ATLAS™ technology platform allows us to
identify immunotherapy targets based on each person’s tumor
antigen-specific T cell responses. Using ATLAS, we can both
optimize neoantigens for inclusion in our immunotherapies and
exclude so-called “inhibitory” antigens that appear to exert an
immunosuppressive effect on the patient. We are advancing
complementary programs built from ATLAS insights: GEN-009, our
neoantigen vaccine candidate for which we are conducting a Phase
1/2a clinical trial across a variety of solid tumor types, and
GEN-011, our neoantigen-specific adoptive T cell therapy, for which
we intend to file an Investigational New Drug Application in the
first half of 2020. To learn more, please visit
www.genocea.com.
Forward Looking StatementsThis press release
includes forward-looking statements, including statements relating
to GEN-009 and GEN-011, within the meaning of the Private
Securities Litigation Reform Act. Such forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied in
such statements. Genocea cautions that these forward-looking
statements are subject to numerous assumptions, risks and
uncertainties that change over time. Applicable risks and
uncertainties include those identified under the heading "Risk
Factors" included in Genocea's Annual Report on Form 10-K for the
year ended December 31, 2018 and any subsequent SEC filings. These
forward-looking statements speak only as of the date of this press
release and Genocea assumes no duty to update forward-looking
statements, except as may be required by law.
Contact: Jennifer LaVin
617-715-6687jennifer.lavin@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genocea Biosciences (NASDAQ:GNCA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Genocea Biosciences Inc (NASDAQ): 0 recent articles
Más de Artículos de Noticias